Africa: HIV Vaccine Research Set to Change Focus in Wake of Mosaico Disappointment

[spotlight] Hopes for the Johnson & Johnson (J&J) Mosaico vaccine – the only HIV vaccine candidate in late-stage (Phase 3) clinical trials – were dashed with manufacturer Janssen Pharmaceuticals’ recent announcement that the vaccine lacked efficacy in preventing HIV infection. In the wake of this announcement, top South African HIV clinicians are now setting their sights on different approaches to finding an HIV vaccine.

Related posts

Leave a Comment

%d bloggers like this: